Alport Syndrome
29
8
11
12
Key Insights
Highlights
Success Rate
80% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
10.3%
3 terminated out of 29 trials
80.0%
-6.5% vs benchmark
10%
3 trials in Phase 3/4
50%
6 of 12 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 12 completed trials
Clinical Trials (29)
NEPTUNE Match Study
Albuminuria Lowering Effect of Dapagliflozin, Spironolactone and Their Combination in Adult Patients With Alport Syndrome (COMBINE-ALPORT)
ASF Alport Patient Registry
A Study to Evaluate Setanaxib in Patients With Alport Syndrome
BAY3401016; Biomarker Study Alport
A Study of ELX-02 in Patients With Alport Syndrome
Vonafexor ALPort Syndrome Efficacy & Safety TRIAl-1 (ALPESTRIA-1)
Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
Alport Syndrome Treatments and Outcomes Registry
Study to Evaluate R3R01 in Patients With Alport Syndrome and Patients With Focal Segmental Glomerulosclerosis
Eurbio-Alport (RaDiCo Cohort) (RaDiCo Eurbio-Alport)
Study of Lademirsen (SAR339375) in Patients With Alport Syndrome
Baby Detect : Genomic Newborn Screening
Atrasentan in Patients With Proteinuric Glomerular Diseases
A Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients With Alport Syndrome - CARDINAL
An Extended Access Program for Bardoxolone Methyl in Patients With CKD (EAGLE)
Alport Therapy Registry - European Initiative Towards Delaying Renal Failure in Alport Syndrome
Human Umbilical Cord Mesenchymal Stem Cells for Alport Syndrome
Effects of Dapagliflozin on Progression of Alport Syndrome
National Registry of Rare Kidney Diseases